Eylea nets an impressive $1.46 billion in second quarter sales

Regeneron Pharmaceuticals reported a significantly better-than-expected quarterly profit, fueled by strong demand for its flagship anti-VEGF drug, aflibercept (Eylea).

According to the company, aflibercept maintained its market-leading position for all approved indications in the United States despite stiff competition from ranibizumab (Lucentis, Novartis).

Aflibercept’s global and U.S net sales both rose 11% in the quarter, and brought in $1.46 billion and $919 million, respectively. Regeneron’s total revenue rose 21% to $1.47 billion, beating analysts’ estimates of $1.35 billion.  

Regeneron also raised its 2017 U.S. growth forecast of aflibercept to approximately 10% over 2016.